Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (291-300 of 333) with videos related to

Pageof 34
Sort By:
Cancer|April 3, 2001
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcomeC Bokemeyer, J P Droz, A Horwich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysisJ T Hartmann, L Einhorn, C R Nichols, et al.
Journal of Cancer Research and Clinical Oncology|August 5, 2005
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levelsM Horstmann, A S Merseburger, E von der Heyde, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2003
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell supportC Kollmannsberger, N Schleucher, O Rick, et al.
Journal of the National Cancer Institute|November 22, 2001
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumorsJ T Hartmann, S D Fossa, C R Nichols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsJ Beck, G Procopio, E Bajetta, et al.
Blood Cancer Journal|February 25, 2017
Mutational landscape reflects the biological continuum of plasma cell dyscrasiasA Rossi, M Voigtlaender, S Janjetovic, et al.
Nature Communications|August 18, 2017
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme BM Wroblewski, R Bauer, M Cubas Córdova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variablesJ Beyer, A Kramar, R Mandanas, et al.
The American Journal of Pathology|October 6, 2000
Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testisH Roelofs, M C Mostert, K Pompe, et al.
Pageof 34

Showing results (291-300 of 333) with videos related to

Sort By:
Pageof 34
Cancer|April 3, 2001
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcomeC Bokemeyer, J P Droz, A Horwich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysisJ T Hartmann, L Einhorn, C R Nichols, et al.
Journal of Cancer Research and Clinical Oncology|August 5, 2005
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levelsM Horstmann, A S Merseburger, E von der Heyde, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2003
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell supportC Kollmannsberger, N Schleucher, O Rick, et al.
Journal of the National Cancer Institute|November 22, 2001
Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumorsJ T Hartmann, S D Fossa, C R Nichols, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsJ Beck, G Procopio, E Bajetta, et al.
Blood Cancer Journal|February 25, 2017
Mutational landscape reflects the biological continuum of plasma cell dyscrasiasA Rossi, M Voigtlaender, S Janjetovic, et al.
Nature Communications|August 18, 2017
Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme BM Wroblewski, R Bauer, M Cubas Córdova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variablesJ Beyer, A Kramar, R Mandanas, et al.
The American Journal of Pathology|October 6, 2000
Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testisH Roelofs, M C Mostert, K Pompe, et al.
Pageof 34